Dacomitinib

DB11963ApprovedInvestigationalSmall molecule

Dacomitinib is a medication used to treat non small cell lung cancer with EGFR exon 19 deletion of exon 21 L858R substitution. Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor...

Chemical structure of Dacomitinib
Mechanism
Curator reviewed · 4 references
Primary indication
Dacomitinib is indicated as the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as verified by an...Curator reviewed · 1 structured indication
Formula / weight
C24H25ClFN5O2 · 469.939 g/mol (avg)
First approval
Canada, 2019 · United States, 2018 · European Union, 2020
Code names
PF-00299804
Brand names
  • Vizimpro

Resolves to

Structure
InChIKeyLVXJQMNHJWSHET-AATRIKPKSA-NSMILESCOC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1

What you can answer from here — as of August 30, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
3TransportersSubstrate / inhibitor direction, not just membership
Listed above
1,365Drug interactionsStructured to mechanism, not free text
Sign in
52Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
25Marketed productsAcross 8 countries and 5 labellers
Sign in
1ATC codeIncluding every combination product, plus 31 drug categories
Sign in
36+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Dacomitinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account